OR WAIT 15 SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
January 01, 2021
Outsourcing increases as the industry balances development and manufacturing of both COVID-19 treatments and non-pandemic-related medicines.
December 09, 2020
Cytiva is adding process development, media and assay development, and contract development services at its facilities in Korea, Japan, Sweden, and the UK.
October 29, 2020
3P Biopharmaceuticals, and Oxford University spin-out, SpyBiotech, have signed a vaccine contract manufacturing agreement.
Catalent has signed an agreement with Bone Therapeutics for the acquisition of Skeletal Cell Therapy Support SA (SCTS).
September 01, 2020
Cellular and gene therapy fields are currently on track for, if not already experiencing, a serious capacity crunch.
July 29, 2020
Sterling Pharma Solutions has signed a deal with Moleculin Biotech to support the development of WP1122, a potential COVID-19 treatment.
July 01, 2020
The COVID-19 pandemic has created a rise in demand for R&D and a shift in focus for some contract organizations.
May 04, 2020
Fujifilm allocates production volumes for COVID-19 treatments in 2021 at its Denmark facility.
May 01, 2020
But are innovations sufficient to increase adoption? CMOs are demanding better continuous bioprocessing options.
April 30, 2020
Catalent and Johnson & Johnson announce joint investment and tech transfer to prepare for rapid scale-up and segregated cGMP commercial manufacturing capacity.